Eisai Wins FDA Approval, Glaxo Seeking Alzheimer’s Investment: Healthcare Business Recap
The Japanese drug developer Eisai (ESALY.PK) wins FDA approval for its Fycompa tablets for the treatment of partial onset seizures in patients suffering from epilepsy. Partial seizures are the most typical type experienced by people with epilepsy.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
GlaxoSmithKline’s (NYSE:GSK) VC fund, SR One, wants to invest in a firm which is developing drugs for the early detection of Alzheimer’s disease along with a treatment for it.
Seattle Genetics (NASDAQ:SGEN) enlarges a collaboration with Abbott Laboratories (NYSE:ABT) through which the latter will pay Seattle an upfront fee of $25 million for the use of its antibody-drug conjugate to help develop treatments for cancer. In addition, Seattle will receive maintenance fees and research support payments for as much as $220 million in milestones and royalties
Don’t Miss: How Healthy are Healthcare Stocks?